IgG

IgG 분자 정보

영어 이름Immunoglobulin G시판 약물 수1
임상 약물 수8표적 별명Immunoglobulin G
최고 연구 개발 단계Approved
영어 이름Immunoglobulin G
표적 별명Immunoglobulin G
시판 약물 수1
임상 약물 수8
최고 연구 개발 단계Approved

IgG 제품 목록

  • 속성

    Antibody (6)

  • 제품 라이브러리

    온라인 (6)

  • Mouse (6)

  • 태그

    - (6)

  • 마커

    HRP Labeled (1)Acridinium ester Labeled (1)Biotin-labeled (1)PE Labeled (1)Europium chelate Labeled (1)FA Labeled (1)

IgG분자 배경

The Anti-Human IgG-Acridine Ester is an acridinium ester labeled Monoclonal mouse anti-human IgG antibody can be used to capture the human IgG in Chemiluminescence procedures. The antibody reacts with the Fc portion of human IgG heavy chain but not with the Fab portion of human IgG. No antibody was detected against human IgM or IgA, or against non-immunoglobulin serum proteins. The antibody has been tested by ELISA and/or solid-phase adsorbed to ensure minimal cross-reaction with mouse, cynomolgus and bovine serum proteins, but it is not sure if the product cross-react with immunoglobulins from other species. Acridinium ester is one of the most commonly used excited substrates for protein labeling and widely used in automated instruments because of its high sensitivity with detection limits in the attomole range. Acridinium ester can be triggering by chemiluminescent substrate solution and generate intense signal, the result signals (relative light units, RLU) can be measured at 430 nm. The Anti-human IgG-Acridine Ester is easy to capture the human IgG, and the bounded human IgG have no activity lost, this ready to use products could greatly save your protein labeling time and hassle, and help us get the best performance and highly reproducible results.

IgG분자 별명

IgG

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
RicefidaseKJ-103; KJ103Phase 3 ClinicalShanghai Bao Pharmaceuticals Co LtdAnti-Glomerular Basement Membrane Disease; Guillain-Barre Syndrome; Rejection of renal transplantation
상세
AT-02AT-02Phase 2 ClinicalAttralus IncAmyloidosis; Immunoglobulin Light-chain Amyloidosis
상세
JZB-34AAFP; JZB-34Phase 1 ClinicalShanghai Kexin Biotech Co LtdHypersensitivity
상세
Emicizumab biosimilar (Jushi Biopharmaceutical)SYS6053; SYS-6053Phase 1 ClinicalJushi Biopharmaceutical Co LtdHemophilia A; Hemorrhage
상세
S-1117S-1117Phase 1 ClinicalSeismic Therapeutics IncImmune System Diseases
상세
BHV-1300BHV-1300Phase 1 ClinicalBiohaven Pharmaceuticals IncArthritis, Rheumatoid; Graves Disease
상세
HNSA-5487HNSA 5487; HNSA-5487Phase 1 ClinicalHansa Biopharma AbAutoimmune Diseases; Neoplasms
상세
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)Phase 1 ClinicalUniversity Of California San DiegoLeukemia, Myeloid, Acute
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
ImlifidaseMac-1ApprovedHansamed IncIdefirixEURejection of renal transplantationHansa Biopharma Ab2020-08-25Guillain-Barre Syndrome; Kidney Diseases; Kidney Failure, Chronic; Purpura, Thrombotic Thrombocytopenic; Rejection of renal transplantation; Rejection of organ transplantation; Renal Insufficiency, Chronic
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호